Is HRT Safe? Understanding the Real Risks and Benefits of Hormone Replacement Therapy

The HRT Controversy: How We Got Here

In 2002, the Women's Health Initiative (WHI) published findings that sent shockwaves through women's healthcare. The study reported increased risks of breast cancer, heart disease, and stroke in women taking combined estrogen-progestogen therapy. Millions of women abruptly stopped their HRT, and prescriptions plummeted by nearly 50% within two years.

But the full picture was more complicated than the headlines suggested. Over the following two decades, re-analysis of WHI data and dozens of new studies have substantially revised our understanding of HRT safety — particularly when therapy is started within a critical window of time after menopause begins.

What the Updated Research Actually Shows

The key reframing is the timing hypothesis, also called the "window of opportunity." Research now consistently shows that HRT initiated within 10 years of menopause onset — or before age 60 — carries a markedly different risk profile than HRT started later in life.

When HRT is started in this early window, cardiovascular risk is neutral or beneficial, all-cause mortality may decrease, breast cancer risk is modest and context-dependent (most significant with combined estrogen-progestogen, not estrogen alone, and comparable in magnitude to drinking 1–2 glasses of wine per night), and stroke and VTE risk is route-dependent — transdermal estrogen carries substantially less clotting risk than oral pills.

Types of HRT and Their Different Risk Profiles

Estrogen-Only HRT

Prescribed for women who have had a hysterectomy, estrogen-only therapy has the most favorable safety data. Studies suggest it may actually reduce breast cancer risk when taken for under 7 years, and provides robust protection against osteoporosis and cardiovascular disease.

Combined Estrogen + Progestogen HRT

Women with a uterus require a progestogen to protect the uterine lining. The type of progestogen matters significantly. Synthetic progestins (like medroxyprogesterone acetate used in the original WHI) carry greater breast and cardiovascular risk than bioidentical progesterone (micronized progesterone), which appears to have a neutral or even protective effect on breast tissue.

Route of Administration

How you take HRT dramatically affects risk. Oral estrogen passes through the liver, elevating clotting factors and triglycerides. Transdermal estrogen (patch, gel, spray) bypasses the liver, offering significantly lower VTE and stroke risk. Vaginal estrogen has local-only effect with virtually no systemic absorption, making it the lowest-risk option for genitourinary symptoms.

For most women, transdermal estrogen is the preferred delivery method from a risk-minimization standpoint.

Who Is a Good Candidate for HRT?

The Menopause Society (formerly NAMS) 2023 position statement affirms that for healthy women under 60 or within 10 years of menopause, the benefits of HRT outweigh the risks for most women. Ideal candidates include women with moderate-to-severe menopausal symptoms (hot flashes, night sweats, sleep disruption, vaginal dryness), women at elevated risk for osteoporosis or with documented bone loss, women under 45 who experienced premature menopause, and women concerned about cardiovascular protection when treatment is started early.

Who Should Generally Avoid HRT?

HRT is generally not recommended for women with a personal history of hormone receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, a history of blood clots (though transdermal estrogen may be lower risk), or a history of stroke or coronary artery disease — especially if more than 10 years post-menopause. These decisions should always be individualized with a knowledgeable clinician.

HRT Benefits Beyond Symptom Relief

Bone Protection

Estrogen is critical to maintaining bone mineral density. Menopause accelerates bone loss — up to 20% of total bone mass can be lost in the first 5–7 years after menopause. HRT is one of the most effective interventions available for preventing osteoporosis and fragility fractures.

Cardiovascular Protection (When Started Early)

Estrogen improves lipid profiles, enhances vasodilation, reduces arterial stiffness, and has anti-inflammatory properties. These benefits appear most pronounced when therapy begins before atherosclerotic plaques have established — hence the critical importance of timing.

Cognitive Function

Emerging evidence suggests early initiation of HRT may have neuroprotective effects, potentially reducing the risk of Alzheimer's disease. Estrogen supports neuronal health, synaptic function, and cerebral blood flow. The "critical window" concept applies here too — late-initiated HRT may not confer these benefits.

Genitourinary Health

The genitourinary syndrome of menopause (GSM) — encompassing vaginal dryness, painful intercourse, urinary urgency, and recurrent UTIs — affects up to 60% of postmenopausal women. Estrogen therapy (particularly local vaginal estrogen) is the most effective treatment. Explore treatments for vaginal dryness for more information.

Duration: How Long Can You Take HRT?

There is no universal rule. The old guidance of "5 years maximum" was based on the misinterpreted WHI data. Current Menopause Society guidance states that duration should be individualized based on symptoms, risk factors, and quality of life. Many women safely continue HRT into their 60s and beyond with appropriate monitoring. Annual review with your clinician allows ongoing risk-benefit reassessment.

The Bottom Line

The evidence-based consensus has shifted significantly since 2002. For most healthy women who begin HRT within 10 years of menopause and have no contraindications, the benefits substantially outweigh the risks. The key is individualized assessment, the right formulation, the right route of administration, and ongoing monitoring. Fear of HRT should not leave women unnecessarily suffering from symptoms that significantly impact quality of life.

References: Manson JE, Aragaki AK, et al. "Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality." JAMA. 2017;318(10):927–938. The Menopause Society. "2023 MMS Hormone Therapy Position Statement." Menopause. 2023;30(7).